* Immunitybio Inc is expected to show a fall in quarterly revenue when it reports results on May 9 (estimated) for the period ending January 1 0001
* The San Diego California-based company is expected to report a 93.1% decrease in revenue to $25 thousand from $360 thousand a year ago, according to the estimate from one analyst, based on LSEG data.
* LSEG's mean analyst estimate for Immunitybio Inc is for a loss of 16 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Immunitybio Inc is $7.50, below its last closing price of $7.81.
This summary was machine generated May 7 at 12:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments